An excellent review/focus from R Storb. His fazit, " Therefore, faced with the choice of an HLA-identical sibling marrow graft or even an alternative donor graft vs immunosuppression, many patients should be counseled in favor of marrow transplantation as first-line therapy." Presenter:Prof. Spyridonidis Participants:Dr. Liga, Dr.Spyridis, Dr Aggelinas
A recent study published in Blood advances "Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia" was presented. Induction led to response in 41% and 32%, survival of 10.8 and 6 months, and transplant in 40% and 42% of responders in MDS...
We discussed the emerging data of the importance of asparaginase in the treatment of ALL. We discussed the potential toxicities and how we can manage them. The time point of application plays after cheotherpay is of major importance. Monitoring for pancreatitis and bleeding should be done routinely. Presenter: Prof....
We discussed the current literature regarding the role of allo HCT in the era of BV and PD1 blockade for HD. Patients with cHL who are ineligible for auto-HCT or relapse after auto-HCT have historically had a poor prognosis with a median survival of 2 years or...
A patient with JAkavi resistant LF who was referred to our unit was presented and discussed. We also presented the current How I treat paper form Blood. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas
The Oncopedia 2018 update on CLL treatment algorithm has presetend and discussed. Presenter: Prof. Spyridondis Partricpants: Dr Liga, Dr Spyridis, Dr Aggelinas
Presenter: Prof. Spyridonidis Participants:Dr Liga, Dr Spyridis, Dr Aggelinas Main studies in newly diagnosed MM (NDMM) presented in 23. Congress, European Hematology Association (EHA), Stockholm, Sweden. ALCYONE NDMM, >65y, auto non-eligible Daratumumab (D) plus Bortezomib-Melphalan-Prednison (VMP) vs VMP more CR, PFS nr vs 20,4 Mo, no problems with addtion of Daratumumab GIMEMA Phase-3, NDMM Bortezomib, Thalidomid-Dexamethason (VTD) vs TD, pre...
Presenter: Dr Liga Participants:Prof. Spyridonidis, Prof. Marangos, Dr Spyridis, Dr Aggelinas
The update of WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES was presented. Presenter: Prof:Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas
Goal of the educational session is to understand the role of DPB1 mismatched in allo Tx. We discussed their level of expression and their alloreactivity as is scored in the TCE algorithm. We also discussed a new proposed methodology which defines the DPB1 alloreactivity...
Scope: To update the current treatment management of CLL in the elderly. Presenter: Dr Spyridis Participants: Prof. Spyridonidis, Dr Liga, Dr Aggelinas.
Based on a case we discussed the current treatment guidelines for essential thrombocythemia. Dr Spyridis presented the current How I treat Blood paper. Presenter: Dr Spyridis Participants: Prof: Spyridonidis, Dr Liga, Dr Aggelinas
We discussed a recent review of the Treatment Options for Carbapenem- Resistant Gram-Negative Infections. We additionally reviewed our current policy in treating these infections and implemented a new policy. Presenter: Prof. Marangos Participants: Prof. Spyridonidis, Dr Spyridis, Dr Liga, Dr Aggelinas.
We discussed novel insights regarding the pathophysiology of CRS after CART therapy published in Nature Medicine. Activation of macrophages plays a major role.
Goal: The Hellenic experience of the use of BV in relapsed HD was presented. The need for transplant after achieving some disease control was discussed. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas.
Goal: We discussed the legislation about SEC and other terms such as GRID. The legislation was presented, especially the specific issue regarding BMT units in Greece which will be presented in EU TE Compenidum. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.
Goal: To understand how PTCY works. We reviewed the current literature of PTCY after related or unrelated Tx. We discussed that the data are premature in order to adopt this strategy. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.
Goal: To understand how PTCY works. We reviewed the current literature of PTCY after related or unrelated Tx. We discussed that the data are premature in order to adapt this strategy. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.
Goal: To present the analysis of our transplant strategy. Results of the analysis of about 100 transplants is shown. Dr Maria Liga presented us her database. Prof. Spyridonidis explained how the data were analysed. The decision to add Cellcept in the case of a...
Goal: The use of TKIs post transplant to prevent relapse. A recent paper describing how sorafenob in mflt3 mutant AML promotes the local GVL effect is presented. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas